Error loading player: No playable sources found
2180
Engineered Probiotics- Latest Advances & Future Outlook
Date
May 3, 2025
This product is not available for individual purchase, but it is available as part of the following products:
Don't miss the opportunity to access the latest research and discoveries in the field of digestive diseases. DDW On Demand is a valuable and convenient way to enhance your knowledge and skills in digestive disease care…
Society: AGA
This session will focus on the latest advances and future outlook of engineered probiotics, highlighting how they differ from existing probiotics. Attendees will learn about the newest approaches to improving probiotics and review pre-clinical data using engineered probiotics. Presentations will cover topics such as engineered E. coli Nissle for IBD, the role of engineered probiotics in IBD, the "BioPersist" treatment for colitis, and the effects of inflammation, dosing frequency, and diet on live bacterial therapeutic engraftment in the gut. Additionally, the session will explore how Akkermansia muciniphila can relieve diarrhea-predominant irritable bowel syndrome via the inosine-A2AR-PPARγ-AQP1 axis.
This session will focus on the latest advances and future outlook of engineered probiotics, highlighting how they differ from existing probiotics. Attendees will learn about the newest approaches to improving probiotics and review pre-clinical data using engineered probiotics. Presentations will cover topics such as engineered E. coli Nissle for IBD, the role of engineered probiotics in IBD, the "BioPersist" treatment for colitis, and the effects of inflammation, dosing frequency, and diet on live bacterial therapeutic engraftment in the gut. Additionally, the session will explore how Akkermansia muciniphila can relieve diarrhea-predominant irritable bowel syndrome via the inosine-A2AR-PPARγ-AQP1 axis.
Moderators
UCSD
Cedars-Sinai Medical Center Inflammatory Bowel Disease Center
